[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Mauser‐Bunschoten et al., 1995 - Google Patents

Effect and side‐effects of alpha interferon treatment in haemophilia patients with chronic hepatitis C

Mauser‐Bunschoten et al., 1995

Document ID
5808621340474310494
Author
Mauser‐Bunschoten E
Bresters D
Reesink H
Roosendaal G
Chamuleau R
Haan E
Jansen P
Van Den Berg H
Publication year
Publication venue
Haemophilia

External Links

Snippet

To evaluate the effect and side‐effects of alpha interferon 2B (IFN) treatment in haemophilia patients with chronic hepatitis C (positive HCV antibody test, positive HCV‐RNA test and ALT levels> 2.5× upper limit of normal) eight HIV and HBs‐ag negative haemophilia patients …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations

Similar Documents

Publication Publication Date Title
KR100254082B1 (en) Composition and method of treating hepatitis-c
Lok et al. Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection
Sáez‐royuela et al. High doses of recombinant α‐interferon or γ‐interferon for chronic hepatitis C: A randomized, controlled trial
Poynard et al. Meta–Analysis of Interferon Randomized Trials in the Treatment of Viral Hepatitis C: Effects of Dose and Duration
Dienstag et al. Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen
Camps et al. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables.
Gaudin et al. The French experience of treatment of chronic type D hepatitis with a 12‐month course of interferon alpha‐2B. Results of a randomized controlled trial
Farrell Therapy of hepatitis C: interferon alfa-n1 trials
Douglas et al. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C: comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM
Negro et al. Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a
Mauser‐Bunschoten et al. Effect and side‐effects of alpha interferon treatment in haemophilia patients with chronic hepatitis C
KR100306024B1 (en) Hepatitis C Therapeutic Composition for Non-Responders to Interferon Therapy
Anderson et al. Randomised controlled trial of lymphoblastoid interferon for chronic active hepatitis B.
Pardo et al. Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony‐stimulating factor plus recombinant interferon‐alpha
Arase et al. Efficacy and changes of the nonstructural 5A GENE by prolonged interferon therapy for patients with hepatitis C virus genotype 1b and a high level of serum HCV-RNA
Marcellin et al. Treatment of chronic viral hepatitis
Schenker et al. Activity and tolerance of a continuous subcutaneous infusion of interferon-α2b in patients with chronic hepatitis C
Pawelec et al. Incidence and treatment of hepatitis C virus infection in children with haemophilia in Poland
Torre et al. Antiviral activity of amantadine in elderly patients with chronic hepatitis C
Simsek et al. Treatment of Chronic Hepatitis C Infection with Interferon α-2 a in a Turkish Population
Terrault et al. Interferons for viral hepatitis
Gonzalez et al. Efficacy of daily induction dosing vs standard thrice weekly dosing of Interferon-α2B for initial treatment of chronic hepatitis C
Picciotto et al. High-dose interferon therapy in patients with chronic hepatitis C: A biochemical and virologic evaluation
Susan Nilsen-Kupsch RDH Antiviral agents and hepatitis C
Colloredo et al. Breakthrough in Chronic Hepatitis C During Recombinant Alpha Interferon Therapy